Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

Study on Durvalumab and Chemotherapy for Patients with Relapsed Stage III Non-Small Cell Lung Cancer After Chemoradiotherapy and Durvalumab Treatment

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of lung cancer known as non-small cell lung cancer (NSCLC). The study is investigating the effects of a treatment called durvalumab, which is also known by its code name MEDI4736. Durvalumab is a medication given as a solution through an infusion, which means it is administered directly into the bloodstream. The purpose of the study is to see if durvalumab can help improve the survival of patients who have relapsed after receiving previous treatments, including chemotherapy and radiation therapy.

The study is divided into two groups, or cohorts. In the first group, researchers are looking at patients who continue to receive durvalumab along with a single chemotherapy drug to see if this combination helps them live longer. In the second group, the study is examining whether continuing durvalumab after initial treatments can improve survival in patients whose cancer has returned. The trial will follow participants over a period of time to monitor their health and any changes in their condition.

Throughout the study, researchers will collect information on how long patients live, how long they remain free from cancer progression, and how their bodies respond to the treatment. They will also monitor the safety of the treatment and any side effects that may occur. This information will help determine the effectiveness of durvalumab in treating relapsed NSCLC and provide insights into potential future treatments for this type of lung cancer.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on specific criteria such as age, weight, and health status. This includes a body weight greater than 30 kg and normal organ and bone marrow function.

    A signed informed consent form is required, indicating understanding and agreement to comply with study requirements.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to evaluate the current health status. This includes tests to confirm the presence of non-small cell lung cancer (NSCLC) and progression during or after previous treatments.

    Tumor tissue is collected for biomarker testing to help guide treatment decisions.

  3. Step 3

    Treatment phase

    The treatment involves the administration of durvalumab, a medication given as a solution for infusion. This is a liquid that is slowly introduced into the bloodstream through a vein.

    The study aims to evaluate the effectiveness of durvalumab in prolonging survival when combined with chemotherapy in patients who have relapsed after previous treatments.

  4. Step 4

    Monitoring and follow-up

    Regular visits are scheduled to monitor health status and response to treatment. This includes checking for any side effects and assessing the progression of the disease.

    The study will track overall survival and progression-free survival, which measures the time during and after treatment that the patient lives with the disease without it getting worse.

  5. Step 5

    Completion of study

    The study is expected to continue until September 2026. Upon completion, final assessments are conducted to evaluate the overall outcomes of the treatment.

    Participants are informed of the results and any further recommendations for their health care.

Who can join the trial?

18 criteria

  • Body weight must be more than 30 kg.
  • Normal organ and bone marrow function is required, which means:
    • Haemoglobin level should be at least 10.0 g/dL without a blood transfusion in the last 28 days.
    • Absolute neutrophil count (ANC) should be at least 1.5 x 109/L.
    • Platelet count should be at least 100 x 109/L.
    • Serum bilirubin should be no more than 1.5 times the normal limit, except for patients with Gilbert’s syndrome.
    • AST (SGOT)/ALT (SGPT) should be no more than 2.5 times the normal limit, or 5 times if liver metastases are present.
    • Creatinine clearance should be at least 51 mL/min, which is a measure of kidney function.
    • Female patients must use effective birth control or abstain from sexual intercourse during the study and for 90 days after the last dose of the study drug.
    • Women must have a negative pregnancy test before starting the study and meet certain criteria to be considered postmenopausal or not able to have children.
    • Male patients must use a condom during sexual intercourse if their partner is pregnant or can become pregnant. Female partners should also use effective birth control if they can become pregnant.
    • Patients must have recurrent or metastatic NSCLC (non-small cell lung cancer) that returned during or after treatment with chemotherapy and durvalumab for stage III disease.
    • Tumor tissue must be available for testing.
    • There must be evidence of disease progression during or after durvalumab treatment, but not within the first three months of starting durvalumab.
    • Patients must have an ECOG performance status of 0 or 1, which indicates they are fully active or have some symptoms but do not need bed rest.
    • Patients must be willing and able to follow the study protocol, including attending visits and undergoing tests.
    • Patients must be at least 18 years old.
    • Patients must be able to give informed consent, which means they understand the study and agree to participate.
    • Patients must have a life expectancy of at least 16 weeks.

Who cannot join the trial?

5 criteria

  • Patients who have a different type of cancer other than NSCLC (non-small cell lung cancer) cannot participate.
  • Patients who are not in the age range specified for the study cannot participate. The study is open to certain age groups only.
  • Patients who are part of a vulnerable population, which means they might need special protection or care, cannot participate.
  • Patients who are not able to follow the study procedures or attend the required visits cannot participate.
  • Patients who have any other medical condition that might interfere with the study or make it unsafe for them cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Durvalumab

    is a medication used in this clinical trial to help improve survival in patients with stage III non-small-cell lung cancer (NSCLC) who have relapsed after previous treatments. It is an immunotherapy drug that works by helping the immune system recognize and attack cancer cells more effectively.

  • Single Agent Chemotherapy

    refers to the use of one chemotherapy drug to treat cancer. In this trial, it is used in combination with durvalumab to see if it can further prolong survival in patients who have progressed during durvalumab maintenance therapy.

What is already known about the treatment

Durvalumab – Durvalumab is administered as an intravenous infusion, typically given in a clinical setting under the supervision of healthcare professionals. It is currently being studied in clinical trials for its effectiveness in treating non-small cell lung cancer (NSCLC), particularly in patients who have relapsed after previous treatments. The main therapeutic indication for durvalumab is to improve survival rates in patients with stage III NSCLC. At the molecular level, durvalumab works by blocking the PD-L1 protein, which helps the immune system recognize and attack cancer cells more effectively. It is classified as an immune checkpoint inhibitor, a type of immunotherapy that enhances the body's natural defenses against cancer.

Investigated diseases

Non-Small Cell Lung Cancer – This is a type of lung cancer that includes several subtypes, such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. It is the most common form of lung cancer, accounting for about 85% of all cases. The disease typically begins in the tissues of the lungs and can spread to other parts of the body. Symptoms may include a persistent cough, chest pain, and shortness of breath. As the disease progresses, it can lead to more severe respiratory issues and other systemic symptoms. Early detection is crucial for managing the disease effectively.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-520081-65-00Protocol codeCONDOREstimated enrolment75 patientsSponsorFondazione Ricerca Traslazionale

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.